Cipla biosimilars plan: 1-2 launches a year to FY31

What Cipla’s CEO said and why it matters

Cipla is building a biosimilars pipeline and plans to add products steadily over the next five years, as it increases its focus on a segment it describes as fast-growing. The company’s management framed biosimilars, respiratory launches, peptides and complex generics as key building blocks for its next phase of growth. At the same time, it acknowledged that investments in these areas have weighed on near-term profitability.

In comments to the media after results, Achin Gupta, managing director and global chief executive officer of Cipla, laid out profitability and growth targets that hinge on new launches and a stronger pipeline. The company also reiterated openness to selective acquisitions and strategic partnerships in the US and Europe to strengthen its differentiated portfolio.

Biosimilars: steady additions over the next 5-6 years

Gupta said Cipla plans to add one to two biosimilars annually over the next five to six years. The company also indicated it is expanding both its own and partnered biosimilars pipeline for the US, with management citing “2-3 internal products plus partnerships” and expecting further expansion.

Cipla’s biosimilars stance in the broader material shared around the story shows a mixed approach of partnering in the near term and building internal assets that are further out. It also reflects capital allocation choices the company has discussed earlier, including a reassessment of what to build in-house versus what to access through external partners.

Near-term profitability pressure from launches and R&D

Cipla’s management said investments in respiratory launches, peptides and complex generics impacted near-term profitability. It also said it “significantly increased” R&D spending during the year to strengthen the pipeline across respiratory, biosimilars and differentiated products for developed markets.

On the margin outlook, Gupta said Cipla expects FY27 EBITDA margins to be 18.5% to 20%, with sequential quarter-on-quarter improvement primarily on the back of new launches. Separately, the material also references FY26 EBITDA margin guidance ranges of 22.75%-24% and 23.5%-24.5%.

US roadmap: respiratory launches, peptides and a new facility

Cipla’s US business is central to its near-term plan. Gupta said the company is preparing for four respiratory launches and one major peptide launch in FY27. He also said Cipla is ramping up supplies from its newly operational Fall River facility in the US.

Cipla recently secured approval for the first AB-rated generic Ventolin from its US site, which Gupta said is expected to be launched in the coming months. The broader pipeline commentary also mentions respiratory generic Advair as a key upcoming product, with one reference pointing to Q4 CY26 and another to the second half of FY26.

In a separate earnings-call summary included in the provided material, Cipla’s US business recorded $126 million in quarterly revenue, with the company describing supply coming from a mix of its own US facilities, India manufacturing, and strategic partners.

FY27 target: US business run-rate of $1 billion

Gupta said Cipla expects the US business run-rate to touch $1 billion by the end of FY27. Another management commentary in the provided text also describes the target as getting “closer to” or “surpass” $1 billion by FY27, depending on launch timing.

The same set of discussions flags pricing pressure and decline risk in Revlimid (lenalidomide) generics. One management comment said Revlimid’s contribution would be “virtually nil to very marginal” in Q3, while also stating the base business is expected to grow sequentially.

India business: Q4 growth led by chronic therapies

Cipla’s India business rose 15% year-on-year to Rs 3,007 crore in Q4, while annual sales grew 9% to Rs 12,680 crore. The company said the growth was led by strong momentum in respiratory, urology, anti-diabetes and cardiac therapies.

The broader material also references Cipla’s focus on deepening its franchise in India and building leadership beyond respiratory into high-growth chronic segments, including cardiometabolic diseases and obesity.

GLP-1 opportunity: Eli Lilly partnership for tirzepatide

Within cardiometabolic care, Gupta identified the GLP-1 weight-loss segment as a key near-term focus. Cipla has partnered with Eli Lilly to market tirzepatide in India, and the provided notes also refer to the launch of Yurpeak (tirzepatide) in obesity care under this partnership.

Gupta said Cipla will prioritise tirzepatide for now, while taking a cautious approach to the emerging opportunity in semaglutide branded generics, which is expected to open up after the molecule goes off patent at the end of March.

Selective inorganic growth and differentiated portfolio

Cipla said it remains open to selective acquisitions and strategic partnerships in the US and European markets to strengthen its differentiated portfolio. Management also described inorganic growth as a strategic pillar, noting that the company has “significant cash reserves” to deploy toward its goals.

Alongside partnerships, Cipla’s stated intent is to move beyond plain generics in respiratory and explore differentiated and specialty opportunities in that category.

Key data points from the updates

Market impact and what investors will track next

For investors, the key tension is between near-term margin pressure and the reliance on a heavier launch calendar to rebuild profitability. Cipla is explicitly linking sequential margin improvement to new launches, while also committing to higher R&D intensity to build future assets.

Execution milestones to watch, based on the company’s own statements, include the timing of the AB-rated generic Ventolin launch, progress on the planned respiratory and peptide launches in FY27, and the ability to scale supplies from the Fall River facility. The company’s approach to biosimilars, adding one to two products annually over the next five to six years, also puts a premium on disciplined partnering and regulatory execution.

Conclusion

Cipla is positioning biosimilars as a long-term growth pillar while leaning on respiratory, peptides and complex generics to support its US ambition of a $1 billion run-rate by FY27. The next few quarters are likely to be shaped by the pace of product launches, ramp-up from the Fall River facility, and the company’s stated goal of sequential margin improvement driven by new launches.